Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Analysts are intrested in these 5 stocks: ( ($JPM) ), ( ($SBUX) ), ( ($HPE) ), ( ($SRPT) ) and ( ($ELV) ). Here is a breakdown of their recent ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to ...

Sarepta stock crashed Friday — wiping out almost all of the gains tied to its restructuring plans — after a third recipient of one of its gene therapies died.According to analysts and several media ...

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

Analyst cuts Sarepta’s rating due to uncertain safety and future revenue potential. ... in our opinion. ... Sarepta Therapeutics stock is down 3.18% at $20.11 at publication on Friday.